Our novel MuteFree™ AAV backbone has been designed, optimized, and validated to enable the generation of AAV transfer vectors with highly stable inverted terminal repeats (ITRs), offering an industry-leading approach to prevent mutations in your vector. This results in gene therapy products with maximum stability for consistent and high-yield manufacturing.
The ITRs play a critical role in AAV packaging and transgene expression. However, these GC-rich regions are highly unstable and prone to mutation, which can lead to increased heterogeneity, decreased viral titers, and lower transgene expression. In the context of clinical development, this can complicate manufacturing, necessitating higher doses to achieve the desired therapeutic effect. Although strategies to mitigate this issue have been developed, including specialized E. coli strains, altered culture conditions, and modified ITR sequences, they are not always effective and may compromise plasmid and AAV yields.
VectorBuilder has engineered a novel AAV transfer vector to safeguard ITR stability: MuteFree™ AAV. Our optimized vector backbone ensures your viral vectors are free of ITR mutations, increasing confidence in gene therapy identity, efficacy, and safety. Meticulously refined and validated by our team of innovators, MuteFree™ delivers the consistency your gene therapy products demand.
Our optimized MuteFree™ AAV backbone can be easily incorporated into existing manufacturing workflows to enable the consistent production of high-titer, high-quality AAV vectors for cell and gene therapies.
服务商工作站 >>
